NASDAQ: AVXL
Anavex Life Sciences Corp Stock Forecast, Predictions & Price Target

Analyst price target for AVXL

Based on 2 analysts offering 12 month price targets for Anavex Life Sciences Corp

Min Forecast
$20.00+444.96%
Avg Forecast
$22.00+499.46%
Max Forecast
$24.00+553.95%

Should I buy or sell AVXL stock?

Based on 2 analysts offering ratings for Anavex Life Sciences Corp.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVXL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVXL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their AVXL stock forecasts and price targets.

AVXL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-28
lockedlocked$00.00+00.00%2025-11-26

1 of 1

Forecast return on equity

Is AVXL forecast to generate an efficient return?

Company
186.36%
Industry
265.15%
Market
230.63%
AVXL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVXL forecast to generate an efficient return on assets?

Company
170.3%
Industry
93.34%
AVXL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVXL earnings per share forecast

What is AVXL's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
$0.58
Avg 3 year Forecast
$1.98

AVXL revenue forecast

What is AVXL's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$263.8M
Avg 2 year Forecast
$134.0M
Avg 3 year Forecast
$331.8M

AVXL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVXL$3.67$22.00+499.46%Strong Buy
DRTS$3.87$9.00+132.56%Buy
RCKT$3.09$39.50+1,178.32%Buy
CLLS$4.71$8.00+69.85%Strong Buy
CTNM$10.49$19.25+83.51%Strong Buy

Anavex Life Sciences Stock Forecast FAQ

Is Anavex Life Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVXL) stock is to Strong Buy AVXL stock.

Out of 2 analysts, 1 (50%) are recommending AVXL as a Strong Buy, 1 (50%) are recommending AVXL as a Buy, 0 (0%) are recommending AVXL as a Hold, 0 (0%) are recommending AVXL as a Sell, and 0 (0%) are recommending AVXL as a Strong Sell.

If you're new to stock investing, here's how to buy Anavex Life Sciences stock.

What is AVXL's earnings growth forecast for 2026-2028?

(NASDAQ: AVXL) Anavex Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.09%.

Anavex Life Sciences's earnings in 2025 is -$46,377,000.On average, 5 Wall Street analysts forecast AVXL's earnings for 2026 to be -$47,086,452, with the lowest AVXL earnings forecast at -$49,034,241, and the highest AVXL earnings forecast at -$45,969,601. On average, 4 Wall Street analysts forecast AVXL's earnings for 2027 to be $51,491,314, with the lowest AVXL earnings forecast at -$12,258,560, and the highest AVXL earnings forecast at $119,145,701.

In 2028, AVXL is forecast to generate $176,802,034 in earnings, with the lowest earnings forecast at $25,392,732 and the highest earnings forecast at $336,797,689.

What is AVXL's revenue growth forecast for 2026-2028?

(NASDAQ: AVXL) Anavex Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.

Anavex Life Sciences's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast AVXL's revenue for 2026 to be $23,573,604,551, with the lowest AVXL revenue forecast at $0, and the highest AVXL revenue forecast at $72,800,837,584. On average, 4 Wall Street analysts forecast AVXL's revenue for 2027 to be $11,968,178,933, with the lowest AVXL revenue forecast at $3,554,982,481, and the highest AVXL revenue forecast at $20,830,617,666.

In 2028, AVXL is forecast to generate $29,644,808,422 in revenue, with the lowest revenue forecast at $9,841,693,986 and the highest revenue forecast at $50,488,828,304.

What is AVXL's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: AVXL) forecast ROA is 170.3%, which is higher than the forecast US Biotechnology industry average of 93.34%.

What is AVXL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVXL price target, the average AVXL price target is $22.00, with the highest AVXL stock price forecast at $24.00 and the lowest AVXL stock price forecast at $20.00.

On average, Wall Street analysts predict that Anavex Life Sciences's share price could reach $22.00 by Nov 28, 2026. The average Anavex Life Sciences stock price prediction forecasts a potential upside of 499.46% from the current AVXL share price of $3.67.

What is AVXL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AVXL) Anavex Life Sciences's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that AVXL's EPS will be -$0.53 for 2026, with the lowest EPS forecast at -$0.55, and the highest EPS forecast at -$0.51. On average, analysts forecast that AVXL's EPS will be $0.58 for 2027, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at $1.33. In 2028, AVXL's EPS is forecast to hit $1.98 (min: $0.28, max: $3.77).

What is AVXL's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: AVXL) forecast ROE is 186.36%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.